Neoadjuvant Therapy of Breast Cancer – what role?

Registo Oncológico Nacional de todos os tumores malignos na população residente em Portugal em 2006, ROR SUL, 2006.

Sorlie T, Perou CM, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2007;98: 70869-70874

Berry D.A., Cronin K.A., Plevritis S.K., et al : Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer. N Engl J Med 2005; 353:7784-7792.

Hortobagyi GN, Blumenschein GR, Spanos W, et al: Multimodal treatment of locoregionally advanced breast cancer. Cancer 7983;57:763-768.

Hutcheon AW, Heys SD, Sarkar TK, et al: Docetaxel primary chemotherapy in breast cancer: a five year update of the Aberdeen trial. Breast Cancer Res. Treat. 2003;82(supplement 7):p. S6.

Rastogi R, Anderson SJ, Bear HD: Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-78 and B-27. J Clin Oncol. 2008; 26: 778-85.

Van der Hage JA, van de Velde CJ, Julien JP, et al: Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 70902. J Clin Oncol. 2007; 79: 4224-37.

Mieog JS, van der Hage JA, van de Velde CJ : Preoperative chemotherapy for women with operable breast cancer. Cochrane Database of Systematic Reviews, no2, 2007; CD005002.

Gianni L, Eiermann W, Semiglazov V, et al : Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neo- adjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomized controlled superiority trial with a parallel HER2-negative cohort. Lancet 2070; 375:377-84.

Tatiana M. Prowell, and Richard Pazdur: Pathological Complete Response and Accelerated Drug Approval in Early Breast Cancer. N Engl J Med; 366: 2438-2447.

Mauri D, Pavlidis N, Ioannidis JP : Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005; 97:788-94.

Cuppone F, Bria E, Carlini P, et al: Taxanes as primary chemotherapy for early breast cancer : meta-analysis of randomized trials. Cancer. 2008; 773:238-46.

Smith IE, A’Hern RP, Coombes GA, et al: A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neoadjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Annals of Oncology. 2004;75:757-758.

Chua S, Smith IE, A’Hern RP, et al: Neoadjuvant vinorelbine/epirubicin (VE) versus standard Adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomized phase III trail (TOPIC 2). Annals of Oncology. 2005;76:7435-7447.

Earl HM, Vallier A, Hiller L, et al: Neo-tAnGo: a neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel+/- gemcitabine in the treatment of women with high-risk early breast cancer (EBC): first report of the primary endpoint, pathological complete response (pCR). J Clin Oncol 2009;27(supplement 75, abstract 522).

Von Minckwitz G, Rezai M, Loibl S, et al: Capecitabine in addition to anthracycline- and taxane- based neoadjuvant treatment in patients with primary breast cancer : phase III GeparQuattro Study. J Clin Oncol. 2070;28:2075-2023.

Mazouni C, Peintinger F, Wan-Kau S, et al : Residual ducatl carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol. 2007;25:2650-2655.

Von Minckwitz G, Untch M, Blohmer JU, et al : Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2072; 30:7796-7804.

Carey LA, Dees EC, Sawyer L, et al: The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes. Clin Cancer Res. 2007 ; 73:2329-34.

Von Minckwitz G, Blohmer JU, Costa S, et al : Neoadjuvant chemotherapy adapted by interim response improves overall survival of primary breast cancer patients- results of the gepartrio trial. Cancer Res 2077; 77(24, abstract S3-2).

Huober J, Hanusch C, Fasching PA, et al: Neoadjuvant chemotherapy of paclitaxel with or without Rad007: results of the non-responder part of the GEPARQUINTO study. Cancer Res. 2077;77(24, abstract 3-6).

Gianni L, Dafni U, Gelber RD, et al: Treatment with trastuzumab for 7 year after adjuvant chemotherapy in patients with HER2-positive

early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2077; 72:236-44.

Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:7673-7684.

Buzdar AU, Ibrahim N, Francis D, et al: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemo- therapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005; 23:3676-3685.

Baselga J, Bradbury I, Eidtmann H, et al: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomized, open-label, multicentre, phase 3 trial. The Lancet. 2072;379:633-40

Gianni L, Pienkowski T, Im Y-H, et al: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflamatory, or early HER 2-positive breast cancer (NeoSphere) : a randomised multicentre, open-label, phase 2 trial. The Lancet Oncology. 2072;73:25-32.

Ismael G, Hegg R, Muehlbauer S, et al: Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncology 2072;73:869 - 878.

Pivot X, Gligorov J, Müller V, et al: Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-

positive early breast cancer (PrefHer): an open-label randomised study. The Lancet Oncology, 2073; 74:962 - 970.

Dowsett M, Smith IE, Ebbs SR, et al: Prognostic value of ki67 expression after short-term presurgical endocrine therapy for primary breast

cancer. J National Cancer Inst. 2007;99:767-770.